1919 Investment Counsel’s AstraZeneca AZN Stock Holding History

1919 Investment Counsel’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$59K	Hold	817	–	–	﹤0.01%	679
2014 Q2	$61K	Buy	817 +317	+63%	+$22.9K	﹤0.01%	677
2014 Q1	$33K	Hold	500	–	–	﹤0.01%	736
2013 Q4	$30K	Hold	500	–	–	﹤0.01%	753
2013 Q3	$26K	Sell	500 -500	-50%	-$25.1K	﹤0.01%	762
2013 Q2	$48K	Buy	+1,000	New	+$50.9K	﹤0.01%	670

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

1919 Investment Counsel's AZN Position: Q3 2014 in Review

1919 Investment Counsel held its AstraZeneca (AZN) position steady in Q3 2014 at 817 shares worth $59K. The position accounts for ﹤0.01% of the portfolio, ranked #679.

1919 Investment Counsel first reported a position in AZN in Q2 2013 and has held it in 6 quarters since. The position peaked at $61K in Q2 2014. 402 funds tracked by Wall St. Rank hold AZN as of Q3 2014.

1919 Investment Counsel held 817 shares of AstraZeneca worth $59K as of Q3 2014.
1919 Investment Counsel left its AstraZeneca share count unchanged in Q3 2014.
AstraZeneca made up ﹤0.01% of 1919 Investment Counsel's portfolio in Q3 2014, its #679 holding.
1919 Investment Counsel first reported a position in AstraZeneca in Q2 2013 and has held it in 6 quarters since.
1919 Investment Counsel's AstraZeneca position peaked at $61K in Q2 2014.
402 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2014.

Based on 1919 Investment Counsel's 13F filing for Q3 2014, filed 14 Nov 2014.